Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.40 |
| ▸ | SSTR5 | P35346 | 2/20 | 0.38 |
| ▸ | FGF1 | P05230 | 2/20 | 0.37 |
| ▸ | FGF2 | P09038 | 2/20 | 0.37 |
| ▸ | VEGFA | P15692 | 2/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925406 | 0.89 | SLC6A2 (0.46) | SLC6A2SLC5A2SSTR5FGF1FGF2 | |
| SCHEMBL16640651 | 0.89 | SLC6A2 (0.40) | SLC6A2SLC5A2SSTR5FGF1FGF2 | |
| SCHEMBL18718066 | 0.89 | SLC6A2 (0.48) | SLC6A2SLC5A2LGALS8PDE4D | |
| SCHEMBL15280895 | 0.87 | FGF1 (0.39) | SLC6A2SSTR5FGF1FGF2VEGFA | |
| SCHEMBL18653425 | 0.86 | SLC6A2 (0.44) | SLC6A2SSTR5FGF1FGF2VEGFA | |
| SCHEMBL15504371 | 0.85 | SLC5A2 (0.47) | SLC6A2SLC5A2 | |
| SCHEMBL14903581 | 0.85 | SLC5A2 (0.47) | SLC6A2SLC5A2 | |
| SCHEMBL14903579 | 0.85 | SLC5A2 (0.47) | SLC6A2SLC5A2 | |
| SCHEMBL15504369 | 0.84 | FGF1 (0.43) | SLC6A2SSTR5FGF1FGF2VEGFA | |
| SCHEMBL18328600 | 0.84 | FGF1 (0.43) | SLC6A2SSTR5FGF1FGF2VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173606-B2 | Sulfated oligosaccharide derivatives | PROGEN PHARMACEUTICALS LIMITED (AU) | 2012-05-08 | — | — | US | disclosed |
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | PROGEN PHARMACEUTICALS LIMITED (AU) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130354-A1 | SULFATED OLIGOSACCHARIDE DERIVATIVES | HPSE, APOB, LIPG | SLC6A2 4286/4885SLC5A2 799/4885SSTR5 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.